These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1734 related items for PubMed ID: 18330088

  • 41. Utility of combined (18)F-fluorodeoxyglucose-positron emission tomography and computed tomography in patients with cervical metastases from unknown primary tumors.
    Roh JL, Kim JS, Lee JH, Cho KJ, Choi SH, Nam SY, Kim SY.
    Oral Oncol; 2009 Mar; 45(3):218-24. PubMed ID: 18804404
    [Abstract] [Full Text] [Related]

  • 42. Impact of F18-fluorodeoxyglycose positron emission tomography/computed tomography on the management of resectable pancreatic tumours.
    Yao J, Gan G, Farlow D, Laurence JM, Hollands M, Richardson A, Pleass HC, Lam VW.
    ANZ J Surg; 2012 Mar; 82(3):140-4. PubMed ID: 22510123
    [Abstract] [Full Text] [Related]

  • 43. 18F-FDG PET/CT as a staging procedure in primary stage II and III breast cancer: comparison with conventional imaging techniques.
    Koolen BB, Vrancken Peeters MJ, Aukema TS, Vogel WV, Oldenburg HS, van der Hage JA, Hoefnagel CA, Stokkel MP, Loo CE, Rodenhuis S, Rutgers EJ, Valdés Olmos RA.
    Breast Cancer Res Treat; 2012 Jan; 131(1):117-26. PubMed ID: 21935602
    [Abstract] [Full Text] [Related]

  • 44. Optimal interpretation of FDG PET in the diagnosis, staging and management of pancreatic carcinoma.
    Delbeke D, Rose DM, Chapman WC, Pinson CW, Wright JK, Beauchamp RD, Shyr Y, Leach SD.
    J Nucl Med; 1999 Nov; 40(11):1784-91. PubMed ID: 10565771
    [Abstract] [Full Text] [Related]

  • 45. Contrast-enhanced 18F-FDG PET/CT: 1-stop-shop imaging for assessing the resectability of pancreatic cancer.
    Strobel K, Heinrich S, Bhure U, Soyka J, Veit-Haibach P, Pestalozzi BC, Clavien PA, Hany TF.
    J Nucl Med; 2008 Sep; 49(9):1408-13. PubMed ID: 18703604
    [Abstract] [Full Text] [Related]

  • 46. Diagnostic accuracy of (18)F-2-deoxy-fluoro-D-glucose positron emission tomography for pN2 lymph nodes in patients with lung cancer.
    Ozawa Y, Hara M, Sakurai K, Nakagawa M, Tamaki T, Nishio M, Shibamoto Y.
    Acta Radiol; 2010 Mar; 51(2):150-5. PubMed ID: 20092375
    [Abstract] [Full Text] [Related]

  • 47.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 48.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 49. The clinical usefulness of 18-fluorodeoxyglucose positron emission tomography in the differential diagnosis, staging, and response evaluation after concurrent chemoradiotherapy for pancreatic cancer.
    Bang S, Chung HW, Park SW, Chung JB, Yun M, Lee JD, Song SY.
    J Clin Gastroenterol; 2006 Mar; 40(10):923-9. PubMed ID: 17063113
    [Abstract] [Full Text] [Related]

  • 50. [Benefit of PET/CT in the preoperative staging in pancreatic carcinomas].
    Kysucan J, Lovecek M, Klos D, Tozzi I, Koranda P, Buriánková E, Neoral C, Havlík R.
    Rozhl Chir; 2010 Aug; 89(7):433-40. PubMed ID: 20925260
    [Abstract] [Full Text] [Related]

  • 51.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 52.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 53.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 54.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 55. Staging of recurrent and advanced lung cancer with 18F-FDG PET in a coincidence technique (hybrid PET).
    Schmid RA, Hautmann H, Poellinger B, Kellner W, Moisseev A, Brinkbaeumer K, Weiss M, Hahn K, Dresel S.
    Nucl Med Commun; 2003 Jan; 24(1):37-45. PubMed ID: 12501018
    [Abstract] [Full Text] [Related]

  • 56. Clinical usefulness of fused PET/CT compared with PET alone or CT alone in nasopharyngeal carcinoma patients.
    Chen YK, Su CT, Ding HJ, Chi KH, Liang JA, Shen YY, Chen LK, Yeh CL, Liao AC, Kao CH.
    Anticancer Res; 2006 Jan; 26(2B):1471-7. PubMed ID: 16619560
    [Abstract] [Full Text] [Related]

  • 57. Feasibility of [18F]FDG-PET and coregistered CT on clinical target volume definition of advanced non-small cell lung cancer.
    Messa C, Ceresoli GL, Rizzo G, Artioli D, Cattaneo M, Castellone P, Gregorc V, Picchio M, Landoni C, Fazio F.
    Q J Nucl Med Mol Imaging; 2005 Sep; 49(3):259-66. PubMed ID: 16172572
    [Abstract] [Full Text] [Related]

  • 58. FDG-PET/CT in restaging of patients with recurrent breast cancer: possible impact on staging and therapy.
    Veit-Haibach P, Antoch G, Beyer T, Stergar H, Schleucher R, Hauth EA, Bockisch A.
    Br J Radiol; 2007 Jul; 80(955):508-15. PubMed ID: 17537758
    [Abstract] [Full Text] [Related]

  • 59. "One-stop-shop" staging: should we prefer FDG-PET/CT or MRI for the detection of bone metastases?
    Heusner T, Gölitz P, Hamami M, Eberhardt W, Esser S, Forsting M, Bockisch A, Antoch G.
    Eur J Radiol; 2011 Jun; 78(3):430-5. PubMed ID: 19945240
    [Abstract] [Full Text] [Related]

  • 60.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 87.